asenapine

Generic Name
asenapine
Brand Names
Saphris, Secuado, Sycrest
Drug Type
Small Molecule
Chemical Formula
C17H16ClNO
CAS Number
65576-45-6
Unique Ingredient Identifier
JKZ19V908O
Background

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as ...

Indication

适用于成人精神分裂症和双相情感障碍患者的治疗。

Associated Conditions
Bipolar 1 Disorder, Mixed manic depressive episode, Schizophrenia, Acute Manic episode
Associated Therapies
Maintenance therapy

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

Investigator Initiated Study - Asenapine Early Psychosis

First Posted Date
2013-10-23
Last Posted Date
2014-01-09
Lead Sponsor
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Target Recruit Count
12
Registration Number
NCT01968161
Locations
🇨🇦

Clinique Notre-Dame des Victoires, Quebec, Canada

Bio-equivalence Study Between SAPHRIS and Asenapine

Phase 1
Completed
Conditions
Interventions
First Posted Date
2013-09-23
Last Posted Date
2021-04-30
Lead Sponsor
Sun Pharmaceutical Industries Limited
Target Recruit Count
65
Registration Number
NCT01948024
Locations
🇺🇸

Woodland International Research Group, Inc., Little Rock, Arkansas, United States

🇺🇸

Collaborative Neuroscience Network, LLC, Garden Grove, California, United States

🇺🇸

Clinical Innovations, Inc, Costa Mesa, California, United States

and more 4 locations

Asenapine for Bipolar Depression

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-03-08
Last Posted Date
2017-07-24
Lead Sponsor
University of Cincinnati
Target Recruit Count
51
Registration Number
NCT01807741
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

Phase 3
Suspended
Conditions
Interventions
First Posted Date
2012-09-13
Last Posted Date
2014-05-20
Lead Sponsor
University of California, Irvine
Target Recruit Count
32
Registration Number
NCT01684657
Locations
🇺🇸

University of California Irvine Medical Center, Orange, California, United States

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

First Posted Date
2012-06-12
Last Posted Date
2024-06-18
Lead Sponsor
Organon and Co
Target Recruit Count
360
Registration Number
NCT01617187

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

First Posted Date
2012-06-12
Last Posted Date
2015-05-27
Lead Sponsor
Forest Laboratories
Target Recruit Count
105
Registration Number
NCT01617200
Locations
🇺🇸

Forest Investigative Site 2001, Austin, Texas, United States

Asenapine in the Treatment of Older Adults With Bipolar Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-10-26
Last Posted Date
2014-12-30
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
15
Registration Number
NCT01460290
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath